MAPT and Alzheimer disease: Recently, the new AD drug “GV-971” developed by China (Shanghai Green Valley Pharmaceutical Co., Ltd., Shanghai, China) reshapes the balance of the gut microbiota, inhibits the abnormal increase in specific metabolites of the gut microbiota, reduces the peripheral and central inflammation, and reduces β-amyloid protein deposition and Tau protein hyper phosphorylation, thereby improving patients’ cognitive dysfunction.